PEbIATRIC BLOOD AND MARROW TRANSPLANT PROGRAM …pub.emmes.com/study/duke/SOP/Clinical/PBMT-GEN-019...
-
Upload
vuongnguyet -
Category
Documents
-
view
219 -
download
0
Transcript of PEbIATRIC BLOOD AND MARROW TRANSPLANT PROGRAM …pub.emmes.com/study/duke/SOP/Clinical/PBMT-GEN-019...
lnfoCard#: PBMT-GEN-019 Rev. 06 Effective Date: 21 Nov 2018
PEbIATRIC BLOOD AND MARROWTRANSPLANT PROGRAM
DOCUMENT NUMBER: PBMT-GEN-019
DOCUIVIENT TITLE:Administration of High Dose Chemotherapy - Cyclophosphamide (Cytoxan)
DOCUMENT NOTES:
Document Information
Revision: 06 Vault: PBMT-General-rel
Status: Release Document Type: General
Date Information
Creation Date: 31 Oct 2018 Release Date: 21 Nov 2018
Effective Date: 21 Nov 2018 Expiration Date:
Control
Author:
Previous
Information
MOORE171
Number: PBMT-GEN-019 Rev 05
Owner:
Change
MOORE171
Number: PBMT-CCR-210
CONFIDENTIAL - Printed by: ACM93 on 21 Nov 2018 08:08:23 am
lnfoCard#: PBMT-GEN-019 Rev. 06 Effective Date: 21 Nov 2018
PBMT-GEN-019ADMINISTRATION OF HIGH DOSE CHEMOTHERAPY -
CYCLOPHOSPHAMIDE (CYTOXAN)
1. PURPOSE
1. 1. To outline the procedure required for the safe administration ofCyclophosphamide
1. 2. To describe the required elements of patient monitoring during and aftercyclophosphamide administration.
2. INTRODUCTION
2. 1. Cyclophosphamide is an alkylating antineoplastic agent which is chemicallyrelated to the nitrogen mustards. It is postulated that the mechanism of cellulartoxicity involves cross-linking of cell DNA.
2.2. The onset ofantineoplastic and immune and bone marrow suppressive effectsoccur within 7-21 days.
2. 3. Adverse effects include but are not limited to nausea, vomiting, hair loss,immunosuppression, secondary malignancies, cardiomyopathy, myocardialnecrosis, dizziness, inappropriate Antidiuretic Hormone (ADH) secretion,hyperkalemia, pancreatitis, pseudomembranous colitis, hemorrhagic cystitis,bladder cancer, sterility, hepatotoxicity, blurred vision, interstitial pneumonitis,pulmonary fibrosis, cellulitis with extravasation, and hypersensitivity withanaphylaxis.
3. SCOPE AND RESPONSIBILITIES
3. 1. Interdisciplinary: Requires an order from a chemotherapy certified physician inthe electronic medical records.
3.2. Registered Nurses (RNs) may administer cyclophosphamide after successfulcompletion of the medication administration test, the chemotherapy certificationtest and demonstration of clinical competency with their preceptors.
4. DEFINITIONS/ACRONYMS
4. 1. ADH Antidiuretic Hormone
4. 2. PPE Personal Protective Equipment
4.3. RN Registered Nurse
5. MATERIALS
5. 1. See the materials section ofPBMT-GEN-069 Administration of ChemotherapyInpatient Unit-5200
PBMT-GEN-019 Administration of High Dose Chemotherapy: Cyclophosphamide - CytoxanPBMT, DUMCDurham, NC Page 1 of 3
CONFIDENTIAL - Printed by: ACM93 on 21 Nov 2018 08:08:23 am
InfoCardff: PBMT-GEN-019 Rev. 06 Effective Date: 21 Nov 2018
6. EQUIPMENT
6. 1. See the equipment section ofPBMT-GEN-069 Administration of ChemotherapyInpatient Unit-5200
7. SAFETY
7. 1. Use appropriate Personal Protective Equipment (PPE) when handlingchemotherapy.
8. PROCEDURE
8. 1.
8.2.
See related SOP titled PBMT-GEN-069 Administration of ChemotherapyInpatient Unit-5200.
Patient Assessment
8.3. Check urine dips and specific gravity with every void.
8. 4. Encourage voiding every 2-3 hours.
8.5. Notify physician or designee for specific gravity greater than (>) 1.020 or bloodin the urine.
8.6. Monitor serum chemistries every 8 hours while administering Cyclophosphamidethis will continue until 24 hours after the completion ofCyclophosphamide.
8.7. Ten hours prior to the administration of Cyclophosphamide change maintenanceIV fluids to D5 3/4NS and increase rate to 2 times maintenance (3000niL/m2/day).This will continue until 24 hours after the completion of the last dose ofCyclophosphamide.
8. 8. Mesna therapy is initiated at the time of the first dose ofCyclophosphamide andcontinues until 24 hours after the last dose of Cyclophosphamide. Mesna isgenerally given as a 24 hour infusion and protects the bladder wall from irritatingCyclophosphamide metabolites.
8. 9. Administration
8. 10. See related SOP titled PBMT-GEN-069 Administration of ChemotherapyInpatient Unit-5200.
9. RELATED DOCUMENTS/FORMS
9. 1. PBMT-GEN-069 Administration of Chemotherapy Inpatient Unit-5200
10. REFERENCES
10. 1. Duke Online Clinical Pharmacology
PBMT-GEN-019 Administration of High Dose Chemotherapy: Cyclophosphamide - CytoxanPBMT, DUMCDurham, NC Page 2 of 3
CONFIDENTIAL - Printed by: ACM93 on 21 Nov 2018 08:08:23 am
lnfoCard#: PBMT-GEN-019 Rev. 06 Effective Date: 21 Nov 2018
11. REVISION HISTORY
Revision No.
06Author
SallyMcCollum
Description of Change(s). Additional statement added to introduction
section: To describe the required elementsof patient monitoring during and aftercyclophosphamide administration.
. Scope and responsibilities further defined toshow chemotherapy certification required:Requires an order from a chemotherapycertified physician in the electronic medicalrecords.
. Outdated SOP updated to correct titlethroughout: PBMT-GEN-069Administration of Chemotherapy InpatientUnit-5200
. Safety Section - statement added: Useappropriate Personal Protective Equipment(PPE) when handling chemotherapy.
. Acronyms defined throughout.
PBMT-GEN-019 Administration of High Dose Chemotherapy: Cyclophosphamide - CytoxanPBMT, DUMCDurham, NC Page 3 of 3
CONFIDENTIAL-Printed by: ACM93on21 Nov 2018 08:08:23 am
InfoCardff: PBMT-GEN-019 Rev. 06 Effective Date: 21 Nov 2018
Signature Manifest
Document Number: PBMT-GEN-019 Revision: 06
Title: Administration of High Dose Chemotherapy - Cyclophosphamide (Cytoxan)All dates and times are in Eastern Time.
PBMT-GEN-019 Administration of High Dose Chemotherapy - Cyclophosphamide (Cytoxan)
Author
Name/Signature Title
Sally McCollum (MOORE171)
Medical Director
I Date Meaning/Reason
05Nov2018, 01:22:18PM Approved
Name/Signature Title
Joanne Kurtzberg(KURTZ001)
Quality
Date Meaning/Reason
05Nov2018, 01:28:10PM Approved
Name/Signature
Bing Shen (BS76)
Document Release
Title Date Meaning/Reason
07 Nov 2018, 10:10:07 AM Approved
Name/Signature Title Date Meaning/Reason
Betsy Jordan (BJ42) 09 Nov 2018, 11:08:25 AM Approved
CONFIDENTIAL - Printed by: ACM93 on 21 Nov 2018 08:08:23 am